Kaempferol

Flavonoid: Anti-angiogenic (VEGF/HIF-1α ↓), pro-apoptotic, PI3K/Akt inhibitor; preclinical adjunct for solid tumors.

AI extractedhuman reviewedsources checkedretractions suppressed

🔬⭐⭐ Preclinical — Robust cell/animal data; human trials limited.3,4',5,7-TetrahydroxyflavoneKMF

Forms: Dietary (e.g., in kale, tea, berries) · Standardized supplement (50-100 mg capsules)

Educational only, not medical advice. OncoForge makes no claim that Kaempferol treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Dietary flavonoid that lowers HIF-1α/VEGF signaling (anti-angiogenic), nudges PI3K/Akt and ERK down, and triggers caspase-mediated apoptosis with G2/M arrest in multiple tumor models. Promising as an adjunct; human oncology trials remain limited.

Evidence at a glance

Tier 1 · labColonBreastLungOvarian

Strong mechanistic preclinical support across models; synergies noted with chemo; human PK/safety established but oncology efficacy unproven.

How it may work

Kaempferol suppresses VEGF and HIF-1α under hypoxia, inhibiting angiogenesis; modulates Bcl-2/Bax with caspase-3/9 activation to induce apoptosis; arrests cells at G2/M via JNK/p38; and inhibits PI3K/Akt and ERK signaling to reduce proliferation and migration. Preclinical efficacy spans colon, breast, lung, and ovarian cancers.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

VEGF↓Hypoxia-induced secretion ↓
HIF-1α↓Protein stability and transcriptional activity ↓
Apoptosis↑Caspase-3/9 activation, Bcl-2/Bax modulation
PI3K/Akt↓Phosphorylation inhibition
ERK↓MAPK signaling dampening
Cell CycleArrestG2/M phase via JNK/p38

VEGFHIF-1αApoptosis

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Cisplatin: Amplified caspase activation and G2/M arrest in ovarian cancer.
Quercetin: Complementary flavonoid effects on apoptosis/cytostasis in breast/colon.
Curcumin: Enhanced VEGF inhibition and anti-proliferative synergy in colorectal models.
Resveratrol: Cooperative apoptosis induction via shared pathways in breast cancer.

Overlapping mechanisms

PI3K/Akt: Redundant with other natural PI3K modulators (e.g., EGCG); prioritize based on bioavailability.
Apoptosis: Multiple pro-apoptotic naturals may saturate caspases without added benefit.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Gi UpsetEstrogenic ActivityAllergy Risk

Potential interactions

anti_angiogenic_agentsMonitorLowTheoreticalAdditive VEGF/HIF-1α suppression may enhance efficacy/toxicity.
pi3k_inhibitorsCautionModerateTheoreticalOverlapping pathway inhibition; potential for amplified cytostasis.
CisplatinSynergizeLowTheoreticalEnhances apoptosis without added nephrotoxicity.

Timing

With-meal: Improves absorption of fat-soluble flavonoid.
AM/PM: Divided doses for steady exposure.

References

Research

No published studies for Kaempferol yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Kaempferol depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 10–100 mg/day (po) divided with meals; dietary sources preferred, Preclinical doses 20-100 µM in vitro; human anti-cancer dosing extrapolated ~50 mg/day; bioavailability low—consider liposomal forms..

Trials studying Kaempferol

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar